Abeona Therapeutics Inc.

ABEO

Healthcare Biotechnology

Abeona Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.8 million, up 66.3% from fiscal 2023.

Revenue
+225.1%
EPS
−116.9%
Free cash flow
+17.1%
Total debt
−23.4%

Quarter to June 2026, against a year earlier

4.17 0.26 +6.65%
Market cap
$238.5M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
2.0×
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
164.58 182.99 204.91 216.13
Total non-current assets
14.93 15.51 5.74 14.97
Total Assets
179.51 198.49 219.57 231.10
Total current liabilities
24.81 31.05 29.57 22.18
Total non-current liabilities
26.64 22.51 30.78 37.68
Total liabilities
51.45 53.56 60.35 59.86
Common Equity (Total)
128.06 144.94 159.22 171.23
Shareholders Equity (Total)
128.06 144.94 159.22 171.23
Total Debt
14.99 18.09 20.04 19.75

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 26 Oct 2026